Back to News
Market Impact: 0.38
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit
Source: GlobeNewswire
Healthcare & BiotechLegal & LitigationRegulation & LegislationCompany Fundamentals
Replimune shareholders who purchased REPL between October 20, 2025 and April 10, 2026 may retain federal securities-law claims after the FDA rejected the biologics license application for RP1. The rejection allegedly wiped out more than 80% of the stock's value during the class period, creating significant litigation and regulatory risk for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.78
Ticker Sentiment
REPL-0.95
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit
- Choosing an AI Copilot for Equity Research